androgen profile, adiponectin, and insulin resistance follow-up assessment for combined metformin and vitamin d treatment for polycystic ovary syndrome

Background & aim: polycystic ovary syndrome (pcos) is the most common endocrine disorder in women of reproductive age (15-44) years. today, (50-80)% of patients with pcos exhibit insulin resistance (ir) syndrome, which is worsened by hyperandrogenism-related adipose tissue accumulation. metformin at a dose of (1700-2000) mg/day, with and without lifestyle is associated with a beneficial improvement on bmi and menstrual cycles. this study investigated the role of androgen profile, insulin resistance and adiponectin to evaluate the benefits of combined vitamin d and metformin in the treatment of pcos. methods: this cross-sectional study was included 50 infertile women who priory diagnosed with pcos with age range (18-40 year). they were classified into; group i:  twenty-five women who were treated with metformin 850 mg/twice daily and followed for 8 weeks. group ii:  twenty-five women who were treated with metformin 850 mg/twice daily plus vitamin d3 50.000 iu/wk., and followed for 8 weeks. serum investigations included measurements of free testosterone, dihydrotestosterone, dehydroepiandrosterone-sulfate, sex-hormone binding globulin, homa-ir, 25-hydroxyvitamin d, and adiponectin, by elisa technique. results: this study revealed that the mean values of free testosterone (p<0.001), dihydrotestosterone (p<0.001) and waist circumference (p<0.021) were significantly improved (by lowering) after treatment with combined metformin plus vitamin d compared with metformin alone. moreover, adiponectin mean value was significantly elevated after combined treatment in compared with metformin alone (p<0.001). conclusion: serum measurements of free testosterone, dihydrotestosterone and adiponectin are good indicators for efficacy of combined metformin plus vitamin d supplement in treatment of pcos women.